Chromogranin a Processing in Human Pituitary Adenomas and Carcinomas: Analysis with Region-specific Antibodies

Overview

Journal Endocr Pathol

Specialties Endocrinology
Pathology

Date 2003 May 15

PMID 12746561

Citations 8

Authors

Long Jin

Shuya Zhang

Jill Bayliss

Bernd Scheithauer

Xiang Qian

Ikuo Kobayashi

Mats Stridsberg

Ricardo V Lloyd

Affiliations

Soon will be listed here.

Abstract

The expression of various chromogranin A (CgA) peptide fragments was examined with region-specific antisera in benign and malignant pituitary tumors. Analysis of the proconvertases responsible for proteolytic processing of CgA, prohormone convertase 1/3 (PC1/3), and PC2 was also performed. Adenomas were studied using tissue microarrays, and a larger tissue section of a subset of the prolactin (PRL) adenomas was used to compare to the tissue microarray analysis. Carcinomas were analyzed using larger tissue sections. There were differences in CgA proteolytic products detected between the functional (PRL, adrenocorticotropic hormone [ACTH], and growth hormone tumors and the nonfunctional (gonadotroph and null cell) tumors, with the former group expressing lower levels of many peptides. These differences were most notable in the PRL adenomas and carcinomas in which the region-specific antisera against vasostatin I and vasostatin II detected these fragments in the lowest percentage of tumors and/or had the weakest immunoreactivity. The CgA peptide fragment detected by CgA 176-195 (chromacin) antiserum was expressed by the highest percentage of most functional and nonfunctional benign and malignant pituitary tumors. ACTH carcinomas (n = 3) were more strongly immunoreactive compared to the ACTH adenomas. These results show that there is differential expression of CgA peptide fragments and PC1/3 among different types of pituitary tumors and that ACTH pituitary carcinomas have higher levels of immunoreactive CgA peptide fragments compared to ACTH adenomas. This study also shows the utility of tissue microarrays in the analysis of a large group of tumors with regionspecific antisera.

Citing Articles

Characterization of the EM66 Biomarker in the Pituitary and Plasma of Healthy Subjects With Different Gonadotroph Status and Patients With Gonadotroph Tumor.

Guillemot J, Guerin M, Cailleux A, Lopez A, Kuhn J, Anouar Y Front Endocrinol (Lausanne). 2019; 10:102.

PMID: 30853937 PMC: 6395403. DOI: 10.3389/fendo.2019.00102.

Genetic aspects of pituitary carcinoma: A systematic review.

Yang Z, Zhang T, Gao H Medicine (Baltimore). 2016; 95(47):e5268.

PMID: 27893664 PMC: 5134857. DOI: 10.1097/MD.0000000000005268.

Immunohistochemical and biochemical studies with region-specific antibodies to chromogranins A and B and secretogranins II and III in neuroendocrine tumors.

Portela-Gomes G, Grimelius L, Stridsberg M Cell Mol Neurobiol. 2010; 30(8):1147-53.

PMID: 21046454 PMC: 11498889. DOI: 10.1007/s10571-010-9585-x.

Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma.

Nakamura N, Erickson L, Jin L, Kajita S, Zhang H, Qian X Endocr Pathol. 2007; 17(3):213-23.

PMID: 17308358 DOI: 10.1385/ep:17:3:213.

Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression.

Ruebel K, Leontovich A, Jin L, Stilling G, Zhang H, Qian X Endocrine. 2006; 29(3):435-44.

PMID: 16943582 DOI: 10.1385/ENDO:29:3:435.

References

Marcinkiewicz M, Day R, Seidah N, Chretien M . Ontogeny of the prohormone convertases PC1 and PC2 in the mouse hypophysis and their colocalization with corticotropin and alpha-melanotropin. Proc Natl Acad Sci U S A. 1993; 90(11):4922-6. PMC: 46625. DOI: 10.1073/pnas.90.11.4922. View

Curry W, Shaw C, Johnston C, Thim L, Buchanan K . Isolation and primary structure of a novel chromogranin A-derived peptide, WE-14, from a human midgut carcinoid tumour. FEBS Lett. 1992; 301(3):319-21. DOI: 10.1016/0014-5793(92)80266-j. View

DeStephano D, Lloyd R, Pike A, Wilson B . Pituitary adenomas. An immunohistochemical study of hormone production and chromogranin localization. Am J Pathol. 1984; 116(3):464-72. PMC: 1900471. View

Jin L, Chandler W, Smart J, England B, Lloyd R . Differentiation of human pituitary adenomas determines the pattern of chromogranin/secretogranin messenger ribonucleic acid expression. J Clin Endocrinol Metab. 1993; 76(3):728-35. DOI: 10.1210/jcem.76.3.7680355. View

MULLER L, Lindberg I . The cell biology of the prohormone convertases PC1 and PC2. Prog Nucleic Acid Res Mol Biol. 1999; 63:69-108. DOI: 10.1016/s0079-6603(08)60720-5. View

Gasparri A, Sidoli A, Sanchez L, Longhi R, Siccardi A, Marchisio P . Chromogranin A fragments modulate cell adhesion. Identification and characterization of a pro-adhesive domain. J Biol Chem. 1997; 272(33):20835-43. DOI: 10.1074/jbc.272.33.20835. View

Fasciotto B, Trauss C, Greeley G, Cohn D . Parastatin (porcine chromogranin A347-419), a novel chromogranin A-derived peptide, inhibits parathyroid cell secretion. Endocrinology. 1993; 133(2):461-6. DOI: 10.1210/endo.133.2.8344192. View

Lloyd R, Wilson B . Specific endocrine tissue marker defined by a monoclonal antibody. Science. 1983; 222(4624):628-30. DOI: 10.1126/science.6635661. View

Winkler H, Fischer-Colbrie R . The chromogranins A and B: the first 25 years and future perspectives. Neuroscience. 1992; 49(3):497-528. PMC: 7131462. DOI: 10.1016/0306-4522(92)90222-n. View

10.

Wiedenmann B, Huttner W . Synaptophysin and chromogranins/secretogranins--widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. Virchows Arch B Cell Pathol Incl Mol Pathol. 1989; 58(2):95-121. DOI: 10.1007/BF02890062. View

11.

Hendy G, Bevan S, Mattei M, Mouland A . Chromogranin A. Clin Invest Med. 1995; 18(1):47-65. View

12.

Singh D, Febbo P, Ross K, Jackson D, Manola J, Ladd C . Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 2002; 1(2):203-9. DOI: 10.1016/s1535-6108(02)00030-2. View

13.

Shi S, Cote C, Kalra K, Taylor C, Tandon A . A technique for retrieving antigens in formalin-fixed, routinely acid-decalcified, celloidin-embedded human temporal bone sections for immunohistochemistry. J Histochem Cytochem. 1992; 40(6):787-92. DOI: 10.1177/40.6.1588025. View

14.

Udupi V, Lee H, Kurosky A, Greeley Jr G . Prohormone convertase-1 is essential for conversion of chromogranin A to pancreastatin. Regul Pept. 1999; 83(2-3):123-7. DOI: 10.1016/s0167-0115(99)00061-0. View

15.

Tatemoto K, Efendic S, Mutt V, Makk G, Feistner G, Barchas J . Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature. 1986; 324(6096):476-8. DOI: 10.1038/324476a0. View

16.

Seidah N, Chretien M . Pro-protein convertases of subtilisin/kexin family. Methods Enzymol. 1994; 244:175-88. DOI: 10.1016/0076-6879(94)44015-8. View

17.

Heaney A, Curry W, Pogue K, Armstrong V, Mirakhur M, Sheridan B . Immunohistochemical evaluation of the post-translational processing of chromogranin A in human pituitary adenomas. Pituitary. 2001; 3(2):67-75. DOI: 10.1023/a:1009949623054. View

18.

Strub J, Goumon Y, Lugardon K, Capon C, Lopez M, Moniatte M . Antibacterial activity of glycosylated and phosphorylated chromogranin A-derived peptide 173-194 from bovine adrenal medullary chromaffin granules. J Biol Chem. 1996; 271(45):28533-40. DOI: 10.1074/jbc.271.45.28533. View

19.

Grimelius L, Johansson H, Wilander E, Stridsberg M . Chromogranin A in human neuroendocrine tumors: an immunohistochemical study with region-specific antibodies. Am J Surg Pathol. 2001; 25(10):1261-7. DOI: 10.1097/00000478-200110000-00006. View

20.

Steiner D, Smeekens S, Ohagi S, Chan S . The new enzymology of precursor processing endoproteases. J Biol Chem. 1992; 267(33):23435-8. View